ReviewFrontiers in oncology2026
Advances in the application of gene methylation detection in cervical cancer screening.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer remains a leading malignancy among women globally, with its pathogenesis strongly associated with persistent high-risk human papillomavirus (HPV) infection. Despite the widespread adoption of HPV testing in cervical cancer screening, its suboptimal specificity frequently results in overdiagnosis and overtreatment. Gene methylation, a key epigenetic modification, has emerged as a highly specific biomarker associated with cervical precancerous lesions and carcinogenesis, holding significant promise for enhancing screening precision. This review comprehensively summarizes recent advances in gene methylation detection for cervical cancer screening, with a focus on the identification of methylation biomarkers, the evolution of detection technologies, and their clinical utility. Furthermore, it addresses the current challenges and limitations in implementing methylation-based assays in routine clinical practice. By offering a systematic overview of the field, this work aims to support the optimization of cervical cancer screening strategies and promote the integration of epigenetic biomarkers into standard clinical workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.